Table 2.

Therapeutic options in patients with chronic coronary syndrome and history of acute coronary syndrome.

Drug	Dose	Indication	References	Recommendation
Clopidogrel	75 mg once daily	Post-MI in patient who have tolerated DAPT for 1 year	DAPT study [32]	IIa, A	IIb, A
Rivaroxaban	2.5 mg twice daily	Post-MI $>$1 year or multivessel CAD	COMPASS trial [33]	IIa, A	IIb, A
Ticagrelor	60 mg twice daily	Post-MI in patient who have tolerated DAPT for 1 year	PEGASUS-TIMI 54 trial [30]	IIa, A	IIb, A
Prasugrel	10 mg once daily or 5 mg once daily (if body weight 60 kg or age $>$75 years)	Post-PCI for MI in patients who have tolerated DAPT for 1 year	DAPT study [32]	IIa, A	IIb, A

$\mathrm{■}$: high ischemic risk without high bleeding risk.

$\mathrm{■}$: moderate ischemic risk without high bleeding risk.

High ischemic risk: Diffuse multivessel CAD with at least one of the following: diabetes mellitus requiring medication, recurrent MI, PAD, or CKD with eGFR 1559 mL/min/1.73 $m^2$.

Moderate ischemic risk: At least one of the following: multivessel/diffuse CAD, diabetes mellitus requiring medication, recurrent MI, PAD, HF, or CKD with eGFR 1559 mL/min/1.73 $m^2$.

High bleeding risk: prior history of intracerebral haemorrhage or ischemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, or renal failure requiring dialysis or with eGFR 15 mL/min/1.73 $m^2$.

MI, myocardial infarctions; DAPT, dual antiplatelet therapy; CAD, coronary artery disease; PCI, percutaneous coronary intervention; PAD, peripheral arterial disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure.